A new experimental drug is showing remarkable promise for children with Dravet syndrome, a severe genetic form of epilepsy.
An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.
A new drug is transforming the lives of children born with a severe form of epilepsy, say doctors and families. Dravet syndrome can cause dozens of dangerous seizures a day and affects about one in ...
Analysts are encouraged by azetukalner’s differentiated MoA and efficacy in epilepsy, as well as the lack of titration needed when prescribing the drug.
Researchers have discovered that mutations in the FOXJ3 gene act as a "master switch" failure, disrupting how the brain ...
Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...
March 9 (Reuters) - Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of showing a statistically significant reduction in focal onset seizures in a late-stage trial ...
Xenon Pharmaceuticals Inc. XENE-Q generated positive results from a critical late-stage human trial for its epilepsy ...
A new experimental treatment for children with a hard-to-treat form of epilepsy is safe and can reduce seizures dramatically, ...
March 9 (Reuters) - Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of showing a statistically significant reduction in focal onset seizures in a late-stage trial ...
Shanghai-based Tenacia Biotechnology is making a $308 million biobucks move for Rapport Therapeutics' leading asset focused on focal onset seizures (FOS) and primary generalized tonic-clonic seizures, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results